QNASL Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Qnasl, and what generic alternatives are available?

Qnasl is a drug marketed by Teva Branded Pharm and is included in one NDA. There are two patents protecting this drug.

This drug has fifty-two patent family members in thirty-two countries.

The generic ingredient in QNASL is beclomethasone dipropionate. There are twenty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the beclomethasone dipropionate profile page.

DrugPatentWatch^® Generic Entry Outlook for Qnasl

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 24, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Try a Trial

Summary for QNASL

International Patents:	52
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	65
Patent Applications:	5,329
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for QNASL
What excipients (inactive ingredients) are in QNASL?	QNASL excipients list
DailyMed Link:	QNASL at DailyMed

Drug patent expirations by year for QNASL

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for QNASL

Generic Entry Date for QNASL^: ⤷ Try a Trial* Constraining patent/regulatory exclusivity: ⤷ Try a Trial NDA: 202813 Dosage: AEROSOL, METERED;NASAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for QNASL

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for QNASL

QNASL is protected by two US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of QNASL is ⤷ Try a Trial.

This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting QNASL

Nasal spray device
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial

Dispensing apparatus with dosage counter
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Branded Pharm	QNASL	beclomethasone dipropionate	AEROSOL, METERED;NASAL	202813-002	Dec 17, 2014		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial	Y			⤷ Try a Trial
Teva Branded Pharm	QNASL	beclomethasone dipropionate	AEROSOL, METERED;NASAL	202813-001	Mar 23, 2012		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y			⤷ Try a Trial
Teva Branded Pharm	QNASL	beclomethasone dipropionate	AEROSOL, METERED;NASAL	202813-002	Dec 17, 2014		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial	Y			⤷ Try a Trial
Teva Branded Pharm	QNASL	beclomethasone dipropionate	AEROSOL, METERED;NASAL	202813-001	Mar 23, 2012		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y			⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for QNASL

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Branded Pharm	QNASL	beclomethasone dipropionate	AEROSOL, METERED;NASAL	202813-002	Dec 17, 2014	⤷ Try a Trial	⤷ Try a Trial
Teva Branded Pharm	QNASL	beclomethasone dipropionate	AEROSOL, METERED;NASAL	202813-001	Mar 23, 2012	⤷ Try a Trial	⤷ Try a Trial
Teva Branded Pharm	QNASL	beclomethasone dipropionate	AEROSOL, METERED;NASAL	202813-001	Mar 23, 2012	⤷ Try a Trial	⤷ Try a Trial
Teva Branded Pharm	QNASL	beclomethasone dipropionate	AEROSOL, METERED;NASAL	202813-001	Mar 23, 2012	⤷ Try a Trial	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for QNASL

When does loss-of-exclusivity occur for QNASL?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Austria

Patent: 7763
Estimated Expiration: ⤷ Try a Trial

European Patent Office

Patent: 58631
Estimated Expiration: ⤷ Try a Trial

Germany

Patent: 2005019404
Estimated Expiration: ⤷ Try a Trial

Spain

Patent: 39574
Estimated Expiration: ⤷ Try a Trial

United Kingdom

Patent: 11384
Estimated Expiration: ⤷ Try a Trial

Patent: 14187
Estimated Expiration: ⤷ Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering QNASL around the world.

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Title	Estimated Expiration
Canada	2004598	AEROSOLS MEDICINAUX (MEDICINAL AEROSOL FORMULATIONS)	⤷ Try a Trial
Hungary	E043276		⤷ Try a Trial
Hong Kong	130397	Aerosol formulation comprising beclomethasone 17,21 dipropionate	⤷ Try a Trial
Australia	658854		⤷ Try a Trial
>Country	>Patent Number	>Title	>Estimated Expiration